Literature DB >> 11059993

Striatal and extra-striatal D(2)/D(3) dopamine receptor occupancy by quetiapine in vivo. [(123)I]-epidepride single photon emission tomography(SPET) study.

C M Stephenson1, V Bigliani, H M Jones, R S Mulligan, P D Acton, D Visvikis, P J Ell, R W Kerwin, L S Pilowsky.   

Abstract

BACKGROUND: Selective action at limbic cortical dopamine D(2)-like receptors could mediate atypical antipsychotic efficacy with few extrapyramidal side-effects. AIMS: To test the hypothesis that quetiapine has 'limbic selective' D(2)/D(3) receptor occupancy in vivo.
METHOD: The high-affinity D(2)/D(3) ligand [(123)I]-epidepride and single photon emission tomography were used to estimate D(2)/D(3) specific binding and an index of relative percentage D(2)/D(3) occupancy in striatal and temporal cortical regions for quetiapine-treated patients (n=6). Quetiapine-, and previously studied typical-antipsychotic- and clozapine-treated patients were compared.
RESULTS: Mean (s.d.) relative percentage D(2)/D(3) receptor occupancy by quetiapine was 32.0% (14.6) in striatum and 60.1% (17.2) in temporal cortex (mean daily dose 450 mg: range 300-700 mg/day). Quetiapine treatment resulted in limbic selective D(2)/D(3) blockade similar to clozapine and significantly higher than typical antipsychotics.
CONCLUSIONS: Preliminary data suggest that limbic selective D(2)/D(3) receptor blockade is important for atypical drug action.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11059993     DOI: 10.1192/bjp.177.5.408

Source DB:  PubMed          Journal:  Br J Psychiatry        ISSN: 0007-1250            Impact factor:   9.319


  13 in total

1.  Quetiapine in Huntington's disease: a first case report.

Authors:  Raphael M Bonelli; Gerald Niederwieser
Journal:  J Neurol       Date:  2002-08       Impact factor: 4.849

2.  Relationship between dose, drug levels, and D2 receptor occupancy for the atypical antipsychotics risperidone and paliperidone.

Authors:  E C Muly; J R Votaw; J Ritchie; L L Howell
Journal:  J Pharmacol Exp Ther       Date:  2012-01-03       Impact factor: 4.030

3.  Non-uniform blockade of intrastriatal D2/D3 receptors by risperidone and amisulpride.

Authors:  James M Stone; Rodrigo A Bressan; Kjell Erlandsson; Peter J Ell; Lyn S Pilowsky
Journal:  Psychopharmacology (Berl)       Date:  2005-09-14       Impact factor: 4.530

4.  Extrastriatal dopamine D(2) receptor occupancy in olanzapine-treated patients with schizophrenia.

Authors:  Ryosuke Arakawa; Hiroshi Ito; Masaki Okumura; Akihiro Takano; Hidehiko Takahashi; Harumasa Takano; Yoshiro Okubo; Tetsuya Suhara
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2009-10-23       Impact factor: 5.270

5.  A new model for separation between brain dopamine and serotonin transporters in 123I-beta-CIT SPECT measurements: normal values and sex and age dependence.

Authors:  Erik Ryding; Mats Lindström; Björn Brådvik; Martin Grabowski; Peter Bosson; Lil Träskman-Bendz; Ingmar Rosén
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-03-11       Impact factor: 9.236

6.  Cortical dopamine D2/D3 receptors are a common site of action for antipsychotic drugs--an original patient data meta-analysis of the SPECT and PET in vivo receptor imaging literature.

Authors:  James M Stone; John M Davis; Stefan Leucht; Lyn S Pilowsky
Journal:  Schizophr Bull       Date:  2008-02-26       Impact factor: 9.306

7.  In vivo affinity of [18F]fallypride for striatal and extrastriatal dopamine D2 receptors in nonhuman primates.

Authors:  Mark Slifstein; Dah-Ren Hwang; Yiyun Huang; Ningning Guo; Yasuhiko Sudo; Raj Narendran; Peter Talbot; Marc Laruelle
Journal:  Psychopharmacology (Berl)       Date:  2004-09       Impact factor: 4.530

Review 8.  Serotonin-glutamate and serotonin-dopamine reciprocal interactions as putative molecular targets for novel antipsychotic treatments: from receptor heterodimers to postsynaptic scaffolding and effector proteins.

Authors:  A de Bartolomeis; E F Buonaguro; F Iasevoli
Journal:  Psychopharmacology (Berl)       Date:  2012-11-21       Impact factor: 4.530

9.  Dopamine D2 receptor levels in striatum, thalamus, substantia nigra, limbic regions, and cortex in schizophrenic subjects.

Authors:  Robert M Kessler; Neil D Woodward; Patrizia Riccardi; Rui Li; M Sib Ansari; Sharlett Anderson; Benoit Dawant; David Zald; Herbert Y Meltzer
Journal:  Biol Psychiatry       Date:  2009-02-28       Impact factor: 13.382

10.  Dose-finding study of paliperidone ER based on striatal and extrastriatal dopamine D2 receptor occupancy in patients with schizophrenia.

Authors:  Ryosuke Arakawa; Hiroshi Ito; Akihiro Takano; Hidehiko Takahashi; Takuya Morimoto; Takeshi Sassa; Katsuya Ohta; Motoichiro Kato; Yoshiro Okubo; Tetsuya Suhara
Journal:  Psychopharmacology (Berl)       Date:  2007-12-06       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.